{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T16:46:25Z","timestamp":1793724385112,"version":"4.6.1"},"reference-count":89,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2024,6,1]]},"abstract":"<jats:sec id=\"ab-nrv240002-1\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Neuropsychiatric syndromes (NPSs) are common in neurodegenerative disorders (NDDs); compromise the quality of life of patients and their care partners; and are associated with faster disease progression, earlier need for nursing home care, and poorer quality of life. Advances in translational pharmacology, clinical trial design and conduct, and understanding of the pathobiology of NDDs are bringing new therapies to clinical care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-nrv240002-2\">\n                    <jats:title>Observations<\/jats:title>\n                    <jats:p>Consensus definitions have evolved for psychosis, agitation, apathy, depression, and disinhibition in NDDs. Psychosocial interventions may reduce mild behavioral symptoms in patients with NDD, and pharmacotherapy is available for NPSs in NDDs. Brexpiprazole is approved for treatment of agitation associated with Alzheimer disease dementia, and pimavanserin is approved for treatment of delusions and hallucinations associated with psychosis of Parkinson disease. Trials are being conducted across several of the NDDs, and a variety of mechanisms of action are being assessed for their effect on NPSs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-nrv240002-3\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>Detection and characterization of NPSs in patients with NDDs is the foundation for excellent care. New definitions for NPSs in NDDs may inform choices regarding clinical trial populations and translate into clinical practice. Psychosocial and pharmacologic therapies may reduce behavioral symptoms and improve quality of life for patients and caregivers. Approved agents may establish regulatory precedents, demonstrate successful trial strategies, and provide the foundation for further advances in treatment development.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaneurol.2024.0586","type":"journal-article","created":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T11:01:11Z","timestamp":1711969271000},"page":"645","source":"Crossref","is-referenced-by-count":50,"title":["Progress in Pharmacologic Management of Neuropsychiatric Syndromes in Neurodegenerative Disorders"],"prefix":"10.1001","volume":"81","author":[{"given":"Jeffrey","family":"Cummings","sequence":"first","affiliation":[{"name":"Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, University of Nevada, Las Vegas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista","family":"Lanctot","sequence":"additional","affiliation":[{"name":"Departments of Psychiatry and Pharmacology, University of Toronto, Sunnybrook Research Institute, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Grossberg","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Neuroscience, Saint Louis University School of Medicine, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clive","family":"Ballard","sequence":"additional","affiliation":[{"name":"Exeter University Medical School, University of Exeter, Exeter, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"nrv240002r1","doi-asserted-by":"publisher","first-page":"04160","DOI":"10.7189\/jogh.13.04160","article-title":"Global, regional, and national burden of neurological disorders in 204 countries and territories worldwide.","volume":"13","author":"Huang","year":"2023","journal-title":"J Glob Health"},{"issue":"4","key":"nrv240002r2","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.jagp.2020.07.011","article-title":"The role of neuropsychiatric symptoms in research diagnostic criteria for neurodegenerative diseases.","volume":"29","author":"Cummings","year":"2021","journal-title":"Am J Geriatr Psychiatry"},{"issue":"1","key":"nrv240002r3","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12877-022-02762-9","article-title":"Neuropsychiatric symptoms and subsyndromes in patients with different stages of dementia in primary care follow-up (NeDEM project): a cross-sectional study.","volume":"22","author":"Garc\u00eda-Mart\u00edn","year":"2022","journal-title":"BMC Geriatr"},{"key":"nrv240002r4","doi-asserted-by":"publisher","DOI":"10.1177\/2050312116661877","article-title":"The influence of caregivers and behavioral and psychological symptoms on nursing home placement of persons with Alzheimer\u2019s disease: a matched case-control study.","volume":"4","author":"Porter","year":"2016","journal-title":"SAGE Open Med"},{"issue":"4","key":"nrv240002r5","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.3233\/JAD-170697","article-title":"The progression of neuropsychiatric symptoms in Alzheimer\u2019s disease during a five-year follow-up: Kuopio ALSOVA Study.","volume":"61","author":"Hallikainen","year":"2018","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"nrv240002r6","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/gps.v33.1","article-title":"Quality of life in relation to neuropsychiatric symptoms in Alzheimer\u2019s disease: 5-year prospective ALSOVA cohort study.","volume":"33","author":"Hongisto","year":"2018","journal-title":"Int J Geriatr Psychiatry"},{"issue":"6","key":"nrv240002r7","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1017\/S1041610219001571","article-title":"Neuropsychiatric symptoms and activities of daily living in Alzheimer\u2019s disease: ALSOVA 5-year follow-up study.","volume":"32","author":"Saari","year":"2020","journal-title":"Int Psychogeriatr"},{"issue":"1","key":"nrv240002r8","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1017\/S1041610217001879","article-title":"Frequency and subgroups of neuropsychiatric symptoms in mild cognitive impairment and different stages of dementia in Alzheimer\u2019s disease.","volume":"30","author":"Siafarikas","year":"2018","journal-title":"Int Psychogeriatr"},{"issue":"17","key":"nrv240002r9","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1212\/WNL.0000000000009323","article-title":"Research criteria for the diagnosis of prodromal dementia with Lewy bodies.","volume":"94","author":"McKeith","year":"2020","journal-title":"Neurology"},{"issue":"3","key":"nrv240002r10","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1093\/brain\/awab365","article-title":"Proposed research criteria for prodromal behavioural variant frontotemporal dementia.","volume":"145","author":"Barker","year":"2022","journal-title":"Brain"},{"issue":"3","key":"nrv240002r11","doi-asserted-by":"publisher","first-page":"929","DOI":"10.3233\/JAD-160979","article-title":"The Mild Behavioral Impairment Checklist (MBI-C): a rating scale for neuropsychiatric symptoms in pre-dementia populations.","volume":"56","author":"Ismail","year":"2017","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"nrv240002r12","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/psyg.v22.3","article-title":"The effects of COVID-19 lockdown on neuropsychiatric symptoms in patients with dementia or mild cognitive impairment: a systematic review and meta-analysis.","volume":"22","author":"Soysal","year":"2022","journal-title":"Psychogeriatrics"},{"issue":"8","key":"nrv240002r13","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1176\/appi.ajp.20220508","article-title":"Dementia is more than memory loss: neuropsychiatric symptoms of dementia and their nonpharmacological and pharmacological management.","volume":"179","author":"Tampi","year":"2022","journal-title":"Am J Psychiatry"},{"key":"nrv240002r14","doi-asserted-by":"publisher","DOI":"10.1017\/S104161022200103X","article-title":"Reduction and prevention of agitation in persons with neurocognitive disorders: an international psychogeriatric association consensus algorithm.","author":"Cummings","year":"2023","journal-title":"Int Psychogeriatr"},{"key":"nrv240002r16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijnurstu.2019.103489","article-title":"Comparative efficacy of non-pharmacological interventions on agitation in people with dementia: a systematic review and Bayesian network meta-analysis.","volume":"102","author":"Leng","year":"2020","journal-title":"Int J Nurs Stud"},{"issue":"3","key":"nrv240002r17","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1017\/S1041610217002344","article-title":"An overview of systematic reviews of pharmacological and non-pharmacological interventions for the treatment of behavioral and psychological symptoms of dementia.","volume":"30","author":"Dyer","year":"2018","journal-title":"Int Psychogeriatr"},{"issue":"1","key":"nrv240002r18","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13024-021-00424-9","article-title":"New approaches to symptomatic treatments for Alzheimer\u2019s disease.","volume":"16","author":"Cummings","year":"2021","journal-title":"Mol Neurodegener"},{"issue":"3","key":"nrv240002r19","doi-asserted-by":"publisher","first-page":"947","DOI":"10.3233\/JAD-180164","article-title":"Effects of meditation and music-listening on blood biomarkers of cellular aging and Alzheimer\u2019s disease in adults with subjective cognitive decline: an exploratory randomized clinical trial.","volume":"66","author":"Innes","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"nrv240002r20","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2023.1167410","article-title":"Eliciting brain waves of people with cognitive impairment during meditation exercises using portable electroencephalography in a smart-home environment: a pilot study.","volume":"15","author":"Lazarou","year":"2023","journal-title":"Front Aging Neurosci"},{"issue":"12","key":"nrv240002r21","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1016\/j.jagp.2020.09.002","article-title":"Criteria for psychosis in major and mild neurocognitive disorders: International Psychogeriatric Association (IPA) consensus clinical and research definition.","volume":"28","author":"Cummings","year":"2020","journal-title":"Am J Geriatr Psychiatry"},{"key":"nrv240002r22","doi-asserted-by":"publisher","DOI":"10.1017\/S1041610222001041","article-title":"Agitation in cognitive disorders: progress in the International Psychogeriatric Association consensus clinical and research definition.","author":"Sano","year":"2023","journal-title":"Int Psychogeriatr"},{"issue":"12","key":"nrv240002r23","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1002\/alz.v17.12","article-title":"Diagnostic criteria for apathy in neurocognitive disorders.","volume":"17","author":"Miller","year":"2021","journal-title":"Alzheimers Dement"},{"issue":"18","key":"nrv240002r24","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1212\/WNL.0000000000011850","article-title":"National Institute of Neurological Disorders and Stroke consensus diagnostic criteria for traumatic encephalopathy syndrome.","volume":"96","author":"Katz","year":"2021","journal-title":"Neurology"},{"issue":"8","key":"nrv240002r25","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1002\/mds.v22:8","article-title":"Diagnostic criteria for psychosis in Parkinson\u2019s disease: report of an NINDS, NIMH work group.","volume":"22","author":"Ravina","year":"2007","journal-title":"Mov Disord"},{"issue":"2","key":"nrv240002r26","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1097\/00019442-200203000-00003","article-title":"Provisional diagnostic criteria for depression of Alzheimer disease.","volume":"10","author":"Olin","year":"2002","journal-title":"Am J Geriatr Psychiatry"},{"issue":"2","key":"nrv240002r27","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1002\/mds.v21:2","article-title":"Provisional diagnostic criteria for depression in Parkinson\u2019s disease: report of an NINDS\/NIMH Work Group.","volume":"21","author":"Marsh","year":"2006","journal-title":"Mov Disord"},{"issue":"pt 9","key":"nrv240002r28","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1093\/brain\/awr179","article-title":"Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia.","volume":"134","author":"Rascovsky","year":"2011","journal-title":"Brain"},{"issue":"6","key":"nrv240002r29","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1111\/ene.v27.6","article-title":"Impulse control and related behaviors in Parkinson\u2019s disease with dementia.","volume":"27","author":"Martinez-Martin","year":"2020","journal-title":"Eur J Neurol"},{"issue":"1","key":"nrv240002r30","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/00019442-200002000-00004","article-title":"Psychosis of Alzheimer\u2019s disease and related dementias. diagnostic criteria for a distinct syndrome.","volume":"8","author":"Jeste","year":"2000","journal-title":"Am J Geriatr Psychiatry"},{"issue":"3","key":"nrv240002r31","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s41582-021-00597-3","article-title":"Psychosis in Alzheimer disease - mechanisms, genetics and therapeutic opportunities.","volume":"18","author":"Ismail","year":"2022","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"nrv240002r32","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrneurol.2016.200","article-title":"The psychosis spectrum in Parkinson disease.","volume":"13","author":"Ffytche","year":"2017","journal-title":"Nat Rev Neurol"},{"issue":"3","key":"nrv240002r33","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1093\/brain\/awaa413","article-title":"Psychosis in neurodegenerative disease: differential patterns of hallucination and delusion symptoms.","volume":"144","author":"Naasan","year":"2021","journal-title":"Brain"},{"issue":"10","key":"nrv240002r34","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.jagp.2019.03.020","article-title":"Delusions in Alzheimer disease are associated with decreased default mode network functional connectivity.","volume":"27","author":"Qian","year":"2019","journal-title":"Am J Geriatr Psychiatry"},{"issue":"12","key":"nrv240002r35","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1038\/mp.2011.125","article-title":"Genome-wide association study of Alzheimer\u2019s disease with psychotic symptoms.","volume":"17","author":"Hollingworth","year":"2012","journal-title":"Mol Psychiatry"},{"issue":"10","key":"nrv240002r36","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1007\/s00415-018-8992-7","article-title":"Neuropsychiatric symptoms and a-synuclein profile of patients with Parkinson\u2019s disease dementia, dementia with Lewy bodies and Alzheimer\u2019s disease.","volume":"265","author":"Bougea","year":"2018","journal-title":"J Neurol"},{"issue":"1","key":"nrv240002r37","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.v7.1","article-title":"Association between regional tau pathology and neuropsychiatric symptoms in aging and dementia due to Alzheimer\u2019s disease.","volume":"7","author":"Tissot","year":"2021","journal-title":"Alzheimers Dement (N Y)"},{"issue":"9916","key":"nrv240002r38","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","article-title":"Pimavanserin for patients with Parkinson\u2019s disease psychosis: a randomised, placebo-controlled phase 3 trial.","volume":"383","author":"Cummings","year":"2014","journal-title":"Lancet"},{"issue":"3","key":"nrv240002r39","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S1474-4422(18)30039-5","article-title":"Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer\u2019s disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study.","volume":"17","author":"Ballard","year":"2018","journal-title":"Lancet Neurol"},{"issue":"4","key":"nrv240002r40","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1056\/NEJMoa2034634","article-title":"Trial of pimavanserin in dementia-related psychosis.","volume":"385","author":"Tariot","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"nrv240002r41","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/nrn1926","article-title":"Neuroleptic drugs in dementia: benefits and harm.","volume":"7","author":"Ballard","year":"2006","journal-title":"Nat Rev Neurosci"},{"key":"nrv240002r42","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2022.101568","article-title":"Pharmacological treatments for psychotic symptoms in dementia: a systematic review with pairwise and network meta-analysis.","volume":"75","author":"Huang","year":"2022","journal-title":"Ageing Res Rev"},{"issue":"4","key":"nrv240002r43","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1001\/archneur.1997.00550160091022","article-title":"Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease.","volume":"54","author":"Bodick","year":"1997","journal-title":"Arch Neurol"},{"issue":"3","key":"nrv240002r44","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.3233\/JAD-215198","article-title":"Behavioral and psychological symptoms of dementia in different dementia disorders: a large-scale study of 10,000 individuals.","volume":"87","author":"Schwertner","year":"2022","journal-title":"J Alzheimers Dis"},{"issue":"5","key":"nrv240002r45","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1176\/appi.ajp.2014.14040480","article-title":"Neuropsychiatric symptoms as predictors of progression to severe Alzheimer\u2019s dementia and death: the Cache County Dementia Progression Study.","volume":"172","author":"Peters","year":"2015","journal-title":"Am J Psychiatry"},{"issue":"1","key":"nrv240002r46","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3233\/JAD-210105","article-title":"Agitation in dementia: real-world impact and burden on patients and the healthcare system.","volume":"83","author":"Jones","year":"2021","journal-title":"J Alzheimers Dis"},{"issue":"12","key":"nrv240002r47","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1001\/archneur.64.12.1755","article-title":"Disruptive behavior as a predictor in Alzheimer disease.","volume":"64","author":"Scarmeas","year":"2007","journal-title":"Arch Neurol"},{"issue":"3","key":"nrv240002r48","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1002\/gps.v34.3","article-title":"Using electronic health records to estimate the prevalence of agitation in Alzheimer disease\/dementia.","volume":"34","author":"Halpern","year":"2019","journal-title":"Int J Geriatr Psychiatry"},{"issue":"9","key":"nrv240002r49","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1111\/jgs.1996.44.issue-9","article-title":"The evolution of psychiatric symptoms in Alzheimer\u2019s disease: a natural history study.","volume":"44","author":"Jost","year":"1996","journal-title":"J Am Geriatr Soc"},{"issue":"3","key":"nrv240002r50","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/cns.2016.22.issue-3","article-title":"Role of donepezil in the management of neuropsychiatric symptoms in Alzheimer\u2019s disease and dementia with Lewy bodies.","volume":"22","author":"Cummings","year":"2016","journal-title":"CNS Neurosci Ther"},{"issue":"2","key":"nrv240002r51","doi-asserted-by":"publisher","first-page":"401","DOI":"10.3233\/JAD-170424","article-title":"Memantine for Alzheimer\u2019s disease: an updated systematic review and meta-analysis.","volume":"60","author":"Kishi","year":"2017","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"nrv240002r52","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jagp.2019.09.009","article-title":"Efficacy and safety of brexpiprazole for the treatment of agitation in Alzheimer\u2019s dementia: two 12-week, randomized, double-blind, placebo-controlled trials.","volume":"28","author":"Grossberg","year":"2020","journal-title":"Am J Geriatr Psychiatry"},{"issue":"12","key":"nrv240002r53","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1001\/jamaneurol.2023.3810","article-title":"Brexpiprazole for the treatment of agitation in Alzheimer dementia: a randomized clinical trial.","volume":"80","author":"Lee","year":"2023","journal-title":"JAMA Neurol"},{"issue":"5","key":"nrv240002r55","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1176\/appi.ajp.2015.173501","article-title":"The American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia.","volume":"173","author":"Reus","year":"2016","journal-title":"Am J Psychiatry"},{"issue":"7","key":"nrv240002r56","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1111\/jgs.v71.7","article-title":"American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults.","volume":"71","author":"2023 American Geriatrics Society Beers Criteria Update Expert Panel","year":"2023","journal-title":"J Am Geriatr Soc"},{"issue":"7","key":"nrv240002r57","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1001\/jama.2014.93","article-title":"Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial.","volume":"311","author":"Porsteinsson","year":"2014","journal-title":"JAMA"},{"issue":"11","key":"nrv240002r58","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/j.jalz.2019.06.4946","article-title":"Escitalopram for agitation in Alzheimer\u2019s disease (S-CitAD): methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial.","volume":"15","author":"Ehrhardt","year":"2019","journal-title":"Alzheimers Dement"},{"issue":"2","key":"nrv240002r59","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.v9.2","article-title":"Alzheimer\u2019s disease drug development pipeline: 2023.","volume":"9","author":"Cummings","year":"2023","journal-title":"Alzheimers Dement (N Y)"},{"issue":"11","key":"nrv240002r60","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1080\/00207454.2020.1730369","article-title":"Analysis of risk factors for depression in Alzheimer\u2019s disease patients.","volume":"130","author":"Yang","year":"2020","journal-title":"Int J Neurosci"},{"issue":"1","key":"nrv240002r61","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1001\/jamapsychiatry.2016.3162","article-title":"Prevalence of depression in patients with mild cognitive impairment: a systematic review and meta-analysis.","volume":"74","author":"Ismail","year":"2017","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"nrv240002r62","doi-asserted-by":"publisher","first-page":"318","DOI":"10.3390\/brainsci13020318","article-title":"Depression in major neurodegenerative diseases and strokes: a critical review of similarities and differences among neurological disorders.","volume":"13","author":"Pagonabarraga","year":"2023","journal-title":"Brain Sci"},{"issue":"3","key":"nrv240002r63","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1212\/CPJ.0000000000000748","article-title":"Validity of the Patient Health Questionnaire-9 in neurologic populations.","volume":"10","author":"Williams","year":"2020","journal-title":"Neurol Clin Pract"},{"issue":"8","key":"nrv240002r64","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.jagp.2014.10.003","article-title":"Development of a brief validated geriatric depression screening tool: the SLU \u201cAM SAD\u201d.","volume":"23","author":"Chakkamparambil","year":"2015","journal-title":"Am J Geriatr Psychiatry"},{"key":"nrv240002r65","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.jad.2022.09.020","article-title":"A meta-analysis of CBT efficacy for depression comparing adults and older adults.","volume":"319","author":"Werson","year":"2022","journal-title":"J Affect Disord"},{"issue":"4","key":"nrv240002r66","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1192\/bjp.bp.114.148130","article-title":"Psychological treatments for depression and anxiety in dementia and mild cognitive impairment: systematic review and meta-analysis.","volume":"207","author":"Orgeta","year":"2015","journal-title":"Br J Psychiatry"},{"issue":"5","key":"nrv240002r67","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.jagp.2020.09.019","article-title":"Preliminary evidence that cortical amyloid burden predicts poor response to antidepressant medication treatment in cognitively intact individuals with late-life depression.","volume":"29","author":"Taylor","year":"2021","journal-title":"Am J Geriatr Psychiatry"},{"issue":"2","key":"nrv240002r68","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.cger.2019.11.007","article-title":"Electroconvulsive therapy in geriatric psychiatry: a selective review.","volume":"36","author":"Meyer","year":"2020","journal-title":"Clin Geriatr Med"},{"issue":"2","key":"nrv240002r69","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.jagp.2021.06.016","article-title":"Apathy as a treatment target in Alzheimer\u2019s disease: implications for clinical trials.","volume":"30","author":"Mortby","year":"2022","journal-title":"Am J Geriatr Psychiatry"},{"issue":"10","key":"nrv240002r70","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1001\/jamapsychiatry.2018.1877","article-title":"Association of apathy with risk of incident dementia: a systematic review and meta-analysis.","volume":"75","author":"van Dalen","year":"2018","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"nrv240002r71","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/gps.v32.3","article-title":"Patterns and persistence of behavioural and psychological symptoms in those with cognitive impairment: the importance of apathy.","volume":"32","author":"van der Linde","year":"2017","journal-title":"Int J Geriatr Psychiatry"},{"key":"nrv240002r72","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/6319826","article-title":"Revisiting apathy in Alzheimer\u2019s disease: from conceptualization to therapeutic approaches.","volume":"2021","author":"Teixeira","year":"2021","journal-title":"Behav Neurol"},{"issue":"2","key":"nrv240002r73","doi-asserted-by":"publisher","DOI":"10.1002\/gps.v38.2","article-title":"Distinguishing apathy from depression: a review differentiating the behavioral, neuroanatomic, and treatment-related aspects of apathy from depression in neurocognitive disorders.","volume":"38","author":"Lanct\u00f4t","year":"2023","journal-title":"Int J Geriatr Psychiatry"},{"key":"nrv240002r74","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2023.1181558","article-title":"The neural correlates of apathy in the context of aging and brain disorders: a meta-analysis of neuroimaging studies.","volume":"15","author":"Yan","year":"2023","journal-title":"Front Aging Neurosci"},{"issue":"4","key":"nrv240002r75","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.jagp.2019.07.014","article-title":"Recommendations for the nonpharmacological treatment of apathy in brain disorders.","volume":"28","author":"Manera","year":"2020","journal-title":"Am J Geriatr Psychiatry"},{"issue":"8","key":"nrv240002r76","doi-asserted-by":"publisher","first-page":"810","DOI":"10.4088\/JCP.12m08099","article-title":"Safety and efficacy of methylphenidate for apathy in Alzheimer\u2019s disease: a randomized, placebo-controlled trial.","volume":"74","author":"Rosenberg","year":"2013","journal-title":"J Clin Psychiatry"},{"issue":"11","key":"nrv240002r77","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1001\/jamaneurol.2021.3356","article-title":"Effect of methylphenidate on apathy in patients with Alzheimer disease: the ADMET 2 randomized clinical trial.","volume":"78","author":"Mintzer","year":"2021","journal-title":"JAMA Neurol"},{"issue":"5","key":"nrv240002r78","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012197.pub2","article-title":"Pharmacological interventions for apathy in Alzheimer\u2019s disease.","volume":"5","author":"Ruthirakuhan","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"nrv240002r79","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.cortex.2020.08.001","article-title":"Cognitive and behavioural inhibition deficits in neurodegenerative dementias.","volume":"131","author":"Migliaccio","year":"2020","journal-title":"Cortex"},{"issue":"3","key":"nrv240002r80","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1080\/14737175.2020.1727740","article-title":"The impact of cognitive and behavioral impairment in amyotrophic lateral sclerosis.","volume":"20","author":"Huynh","year":"2020","journal-title":"Expert Rev Neurother"},{"issue":"1","key":"nrv240002r81","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.30194","article-title":"Progression of behavioral disturbances and neuropsychiatric symptoms in patients with genetic frontotemporal dementia.","volume":"4","author":"Benussi","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"12","key":"nrv240002r82","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1136\/jnnp-2013-307343","article-title":"Neuropsychiatric symptoms in a European Huntington\u2019s disease cohort (REGISTRY).","volume":"85","author":"van Duijn","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"pt 9","key":"nrv240002r83","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.1093\/brain\/awr173","article-title":"Convergent grey and white matter evidence of orbitofrontal cortex changes related to disinhibition in behavioural variant frontotemporal dementia.","volume":"134","author":"Hornberger","year":"2011","journal-title":"Brain"},{"issue":"3","key":"nrv240002r84","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1590\/1980-57642021dn15-030004","article-title":"Treatment of the behavioral variant of frontotemporal dementia: a narrative review.","volume":"15","author":"Gambogi","year":"2021","journal-title":"Dement Neuropsychol"},{"issue":"4","key":"nrv240002r85","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.jagp.2017.10.008","article-title":"Effectiveness of dextromethorphan\/quinidine in frontotemporal dementia.","volume":"26","author":"Chen","year":"2018","journal-title":"Am J Geriatr Psychiatry"},{"issue":"4","key":"nrv240002r87","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1002\/alz.v18.4","article-title":"Diversity in Alzheimer\u2019s disease drug trials: the importance of eligibility criteria.","volume":"18","author":"Franzen","year":"2022","journal-title":"Alzheimers Dement"},{"issue":"1","key":"nrv240002r88","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s40259-023-00633-2","article-title":"Anti-amyloid monoclonal antibodies for the treatment of Alzheimer\u2019s disease.","volume":"38","author":"Cummings","year":"2024","journal-title":"BioDrugs"},{"issue":"2","key":"nrv240002r89","doi-asserted-by":"publisher","first-page":"197","DOI":"10.14283\/jpad.2022.30","article-title":"Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease.","volume":"9","author":"Budd Haeberlein","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"key":"nrv240002r15","first-page":"528","article-title":"Agitation in Alzheimer\u2019s disease: a decision tree for healthcare providers.","volume-title":"Innov Aging","author":"Grossberg","year":"2022"},{"key":"nrv240002r86","author":"Grossberg"},{"key":"nrv240002r54","unstructured":"Discover REXULTI (brexpiprazole). Otsuka America Pharmaceutical. Accessed June 1, 2023. https:\/\/www.rexultihcp.com\/"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2816507\/jamaneurology_cummings_2024_rv_240002_1717440882.92863.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T11:12:33Z","timestamp":1718017953000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2816507"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2024,6,1]]},"references-count":89,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2024.0586","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,1]]}}}